PL372919A1 - Pochodne tiazolidynokarboksyamidu jako modulatoryreceptora prostaglandyny F - Google Patents

Pochodne tiazolidynokarboksyamidu jako modulatoryreceptora prostaglandyny F

Info

Publication number
PL372919A1
PL372919A1 PL03372919A PL37291903A PL372919A1 PL 372919 A1 PL372919 A1 PL 372919A1 PL 03372919 A PL03372919 A PL 03372919A PL 37291903 A PL37291903 A PL 37291903A PL 372919 A1 PL372919 A1 PL 372919A1
Authority
PL
Poland
Prior art keywords
prostaglandin
modulators
receptor
carboxamide derivatives
thiazolidine carboxamide
Prior art date
Application number
PL03372919A
Other languages
English (en)
Inventor
Patrick Page
Catherine Jorand-Lebrun
Anna Quattropani
Vincent Pomel
Matthias Schwarz
Estelle Hamelin
Russell J. Thomas
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of PL372919A1 publication Critical patent/PL372919A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL03372919A 2002-03-28 2003-03-27 Pochodne tiazolidynokarboksyamidu jako modulatoryreceptora prostaglandyny F PL372919A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02100314 2002-03-28

Publications (1)

Publication Number Publication Date
PL372919A1 true PL372919A1 (pl) 2005-08-08

Family

ID=28459561

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372919A PL372919A1 (pl) 2002-03-28 2003-03-27 Pochodne tiazolidynokarboksyamidu jako modulatoryreceptora prostaglandyny F

Country Status (21)

Country Link
US (2) US20050215605A1 (pl)
EP (1) EP1487442B1 (pl)
JP (1) JP4602672B2 (pl)
KR (1) KR20040095311A (pl)
CN (1) CN100484524C (pl)
AT (1) ATE489951T1 (pl)
AU (2) AU2003240757B2 (pl)
BR (1) BR0308748A (pl)
CA (1) CA2477265A1 (pl)
DE (1) DE60335175D1 (pl)
EA (1) EA007328B1 (pl)
ES (1) ES2360882T3 (pl)
HR (1) HRP20040759A2 (pl)
IL (1) IL164212A0 (pl)
MX (1) MXPA04009374A (pl)
NO (1) NO20044262L (pl)
PL (1) PL372919A1 (pl)
RS (1) RS81604A (pl)
UA (1) UA78021C2 (pl)
WO (1) WO2003082278A1 (pl)
ZA (1) ZA200406763B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335175D1 (de) * 2002-03-28 2011-01-13 Merck Serono Sa Thiazolidin-carbonsäureamid-derivate als modulatoren des prostaglandin-f-rezeptors
ATE552236T1 (de) 2003-01-14 2012-04-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
MY150129A (en) 2004-04-09 2013-11-29 Archer Daniels Midland Co Method of preparing fatty acid alkyl esters from waste or recycled fatty acid stock
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
EP2735566A1 (en) * 2006-02-07 2014-05-28 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
US20090163586A1 (en) 2007-12-20 2009-06-25 Astrazeneca Ab Bis-(Sulfonylamino) Derivatives in Therapy 205
WO2011014649A1 (en) 2009-07-29 2011-02-03 Duke University Compositions and methods for inhibiting hair growth
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
JP2014527511A (ja) 2011-06-24 2014-10-16 アムジエン・インコーポレーテツド Trpm8拮抗剤及び治療におけるそれらの使用
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US20160264536A1 (en) 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN109790133A (zh) 2016-01-04 2019-05-21 奥布赛瓦股份公司 羟丙基噻唑烷羧酰胺衍生物的α-氨基酯及其盐形式、晶体多形体
CA3009576A1 (en) * 2016-01-04 2017-07-13 Merck Serono S.A. L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
US9447055B1 (en) 2016-01-04 2016-09-20 Merck Serono S.A. α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
EA202092538A1 (ru) * 2016-10-13 2021-05-31 Мерк Сероно С.А. Альфа-сложные аминоэфиры производного гидроксипропилтиазолидин карбоксамида и его солевая форма, кристаллический полиморф
US11289654B2 (en) 2016-12-22 2022-03-29 Guangzhou Chinaray Optoelectronic Materials Ltd. Polymers containing furanyl crosslinkable groups and uses thereof
US11534428B1 (en) 2018-05-16 2022-12-27 Xoma (Us) Llc Compositions and methods for delaying the incidence of labor
JP2023550555A (ja) 2020-11-16 2023-12-01 ゾーマ(ユーエス) エルエルシー 早期分娩の治療または予防のための組成物及び方法
US20240024295A1 (en) * 2020-12-11 2024-01-25 Elise A. Olsen Compositions and methods for inhibiting hair growth
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016270A (en) * 1975-10-31 1977-04-05 Alza Corporation Method for treating dysmenorrhea with a uterine therapeutic system
JPH0662529B2 (ja) * 1984-07-13 1994-08-17 三共株式会社 アミノ酸誘導体
JPS6450818A (en) * 1987-08-20 1989-02-27 Tsumura & Co Prostaglandin f2alpha-inhibitor
US5338755A (en) * 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
US6271201B1 (en) * 1993-07-15 2001-08-07 Board Of Regents, The University Of Texas System Methods for the selective regulation of placental prostanoids and inhibition of labor using IGF-I
DE69716934T2 (de) * 1996-08-28 2003-07-31 The Procter & Gamble Company, Cincinnati 1,3-diheterozyklische metalloprotease inhibitoren
WO1999006436A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6645939B1 (en) * 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
DE60335175D1 (de) * 2002-03-28 2011-01-13 Merck Serono Sa Thiazolidin-carbonsäureamid-derivate als modulatoren des prostaglandin-f-rezeptors

Also Published As

Publication number Publication date
RS81604A (sr) 2006-12-15
EA007328B1 (ru) 2006-08-25
BR0308748A (pt) 2005-01-11
ATE489951T1 (de) 2010-12-15
MXPA04009374A (es) 2005-01-25
ES2360882T3 (es) 2011-06-10
AU2003240757B2 (en) 2008-07-03
HK1075215A1 (zh) 2005-12-09
UA78021C2 (en) 2007-02-15
CN100484524C (zh) 2009-05-06
ZA200406763B (en) 2005-09-30
DE60335175D1 (de) 2011-01-13
HRP20040759A2 (en) 2004-12-31
AU2008207407A1 (en) 2008-09-11
CN1655780A (zh) 2005-08-17
WO2003082278A1 (en) 2003-10-09
US20090215749A9 (en) 2009-08-27
US20080255094A1 (en) 2008-10-16
EP1487442A1 (en) 2004-12-22
AU2003240757A1 (en) 2003-10-13
US8415480B2 (en) 2013-04-09
JP2005531524A (ja) 2005-10-20
NO20044262L (no) 2004-10-07
JP4602672B2 (ja) 2010-12-22
CA2477265A1 (en) 2003-10-09
US20050215605A1 (en) 2005-09-29
KR20040095311A (ko) 2004-11-12
IL164212A0 (en) 2005-12-18
EP1487442B1 (en) 2010-12-01
EA200401270A1 (ru) 2005-02-24

Similar Documents

Publication Publication Date Title
PL372919A1 (pl) Pochodne tiazolidynokarboksyamidu jako modulatoryreceptora prostaglandyny F
MXPA05013366A (es) Derivados de benzazepina utiles para el tratamiento de enfermedades asociadas con el receptor 5ht2c.
AU2004212335A8 (en) Piperazine-2-carboxamide derivatives
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
NO20073465L (no) Benzotiazol-derivater
MY135841A (en) Novel benzodioxoles
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
YU84603A (sh) Novi inhibitori tirozin kinaze
MXPA03010232A (es) Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
PH12022500015A1 (en) Ccr6 receptor modulators
IL161047A0 (en) Pyrazole derivatives for increasing endogenous testosterone levels
MX2025012483A (es) Moduladores de nk3 y usos de los mismos
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
EA200401423A1 (ru) Пиперазинбензотиазолы, используемые в качестве средств для лечения церебральных ишемических расстройств или расстройств цнс
IL161116A (en) Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary arterial hypertension
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
PL381614A1 (pl) Pochodne indol-2-onu do leczenia chorób centralnego układu nerwowego, chorób układu pokarmowego oraz chorób układu krążenia

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)